Home › Funds › Opaleye Management Inc. › RYTM

Opaleye Management Inc. position in RYTM

RHYTHM PHARMACEUTICALS INC · Health Care

Opaleye Management Inc. reported holding 122,500 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$13.6M, representing 1.23% of its reported portfolio and ranking #23 among its reported holdings. Opaleye Management Inc. has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)122.50K sh
Reported value held$13.60M
Portfolio Weight1.23%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Opaleye Management Inc.'s RYTM position evolved

Opaleye Management Inc. first disclosed a stake in RYTM in Q3 2023 at 653,000 shares (US$15.0M). The position peaked in Q3 2025 at 461,700 shares, worth US$46.6M. Across 12 filings, Opaleye Management Inc. increased the stake 0 time(s), trimmed it 8 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 122,500 shares valued at US$13.6M. Notable position changes include a 29% trim in Q4 2025 (shares fell 19% over the following quarter), a 63% trim in Q1 2026 (shares rose 28% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 653.00K $14.97M New
Q4 2023 610.00K $28.04M Reduce
Q1 2024 515.00K $22.31M Reduce
Q2 2024 515.00K $21.15M Hold
Q3 2024 500.00K $26.20M Reduce
Q4 2024 500.00K $27.99M Hold
Q1 2025 490.00K $25.96M Reduce
Q2 2025 475.00K $30.02M Reduce
Q3 2025 461.70K $46.63M Reduce
Q4 2025 330.00K $35.32M Reduce
Q1 2026 123.00K $35.32M Reduce
Q2 2026 122.50K $13.60M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 52 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has Opaleye Management Inc. held RYTM?

Opaleye Management Inc. has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Opaleye Management Inc.'s current position in RYTM?

As of Q2 2026, Opaleye Management Inc. holds 122.50K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $13.60M, representing 1.23% of its reported portfolio and ranking #23.

Has Opaleye Management Inc. been buying or selling RYTM?

In the latest 13F filing (Q2 2026), Opaleye Management Inc. held unchanged its position in RYTM. The position peaked in Q3 2025 at 461.70K shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.